Catalyst Pharmaceuticals Inc (CPRX)

Working capital turnover

		Dec 31, 2023	Sep 30, 2023	Jun 30, 2023	Mar 31, 2023	Dec 31, 2022	Sep 30, 2022	Jun 30, 2022	Mar 31, 2022	Dec 31, 2021	Sep 30, 2021	Jun 30, 2021	Mar 31, 2021	Dec 31, 2020	Sep 30, 2020	Jun 30, 2020	Mar 31, 2020	Dec 31, 2019	Sep 30, 2019	Jun 30, 2019	Mar 31, 2019
Revenue (ttm)	US$ in thousands	398,204	348,393	302,949	256,480	214,203	191,755	170,465	153,717	140,833	133,539	126,902	120,142	119,073	118,181	119,761	118,994	102,306	72,683	41,786	12,948
Total current assets	US$ in thousands	219,329	192,017	240,968	198,911	320,806	276,310	242,558	221,191	210,106	192,795	176,305	161,533	159,244	143,342	131,164	116,944	111,364	90,579	72,056	54,862
Total current liabilities	US$ in thousands	76,063	57,806	52,503	56,709	57,588	44,681	22,488	22,938	27,063	20,614	16,135	14,436	22,756	18,232	20,210	17,636	24,099	17,982	14,152	9,026
Working capital turnover		2.78	2.60	1.61	1.80	0.81	0.83	0.77	0.78	0.77	0.78	0.79	0.82	0.87	0.94	1.08	1.20	1.17	1.00	0.72	0.28

December 31, 2023 calculation

Working capital turnover = Revenue (ttm) ÷ (Total current assets – Total current liabilities)
= $398,204K ÷ ($219,329K – $76,063K)
= 2.78

The working capital turnover for Catalyst Pharmaceuticals Inc has shown fluctuations over the periods analyzed. The metric indicates how efficiently the company is utilizing its working capital to generate sales revenue. A higher turnover ratio signifies more effective management of working capital.

Between December 2019 and June 2020, the working capital turnover was relatively low, indicating that the company was generating less revenue per unit of working capital invested. However, from March 2020 onwards, there was a noticeable improvement in the ratio, with a consistent upward trend until December 2022.

The period between December 2022 and June 2023 saw a decline in the working capital turnover ratio, which may suggest less efficient utilization of working capital during that timeframe. However, starting from September 2023, there was a rebound in the ratio, indicating a potential improvement in the company's working capital efficiency.

Overall, the working capital turnover ratio for Catalyst Pharmaceuticals Inc has displayed variability, likely influenced by changes in sales revenue and working capital management practices. It is essential for the company to monitor and optimize this metric to ensure efficient utilization of its resources in driving revenue growth.